Overview

68Ga-P16-093 and 18F-FDG PET/CT Imaging in the Same Group of Clear Cell Renal Cell Carcinoma Patients

Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
0
Participant gender:
All
Summary
PSMA is highly expressed on the cell surface of the microvasculature of several solid tumors, including clear cell renal cell carcinoma (ccRCC). This makes it a potentially imaging target for the detection of ccRCC. This pilot study was designed to evaluate the diagnostic performance of 68Ga-P16-093, a novel radiopharmaceutical targeting PSMA, which was compared with 18F-FDG PET/CT in the same group of ccRCC patients.
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Peking Union Medical College Hospital
Treatments:
Fluorodeoxyglucose F18
Criteria
Inclusion Criteria:

- patients with confirmed or suspected clear cell Renal cell carcinoma;

- 68Ga-P16-093 18F-FDG PET/CT within a week;

- signed written consent.

Exclusion Criteria:

- pregnancy;

- breastfeeding;

- known allergy against PSMA;

- any medical condition that in the opinion of the investigator may significantly
interfere with study compliance.